Adoptive immunotherapy for treating cancer

1. A pharmaceutical composition comprising a therapeutically effective number of breast cancer specific TILs produced and/or expanded ex vivo by

i) obtaining one or more tumor fragments from a patient in need of cancer treatment,

ii) contacting said one or more tumor fragments with a TIE-2 and a VEGFR kinase inhibitor,

iii) culturing said one or more tumor fragments in the presence of one or more growth promoting substances,

iv) expanding said TILs, and

v) recovering the expanded TILs.

2. The pharmaceutical composition of claim 1 , wherein the expanded recovered breast cancer specific TILs are CD4 and/or CD8.

3. The pharmaceutical composition of claim 2 , wherein the breast cancer specific TILs are CD8 that express high levels of CD137, CD28 and BTLA.

4. The pharmaceutical composition of claim 2 , wherein the CD4 and/or CD8 display a stem cell memory phenotype (TSCM).

5. The pharmaceutical composition of claim 1 , further comprising a therapeutically effective amount of a cytokine selected from the group consisting of a chemokine, an interleukin, an interferon (IFN-α or IFN-δ) and a combination of two or more of these cytokines.

6. The pharmaceutical composition of claim 5 , wherein the interleukin is selected from the group consisting of interleukin-2, interleukin-4, interleukin-6, interleukin-7, interleukin-12, interleukin-15, interleukin-21, a functionally similar interleukin, and a combination of two or more of these interleukins.

7. A kit comprising

a pharmaceutical composition comprising a therapeutically effective number of breast cancer specific TILs produced and/or expanded ex vivo by

i) obtaining one or more tumor fragments from a patient in need of cancer treatment,

ii) contacting said one or more tumor fragments with a TIE-2 and a VEGFR kinase inhibitor,

iii) culturing said one or more tumor fragments in the presence of one or more growth promoting substances,

iv) expanding said TILs, and

v) recovering the expanded TILs.